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ABSTRACT  
Changes in protein concentrations within human blood are used as an indicator for nutritional state, 
hydration and underlying illnesses. They are often measured at regular clinical appointments and the 
current analytical process can result in long waiting times for results and the need for return patient 
visits. Attenuated total reflectance – Fourier transform infrared (ATR-FTIR) spectroscopy has the 
ability to detect minor molecular differences, qualitatively and quantitatively, in biofluid samples, 
without extensive sample preparation. ATR-FTIR can return an analytical measurement almost 
instantaneously and therefore could be deemed as an ideal technique for monitoring molecular 
alterations in blood within the clinic.  
To determine the suitability of using ATR-FTIR spectroscopy to enable protein quantification in a 
clinical setting, pooled human serum samples spiked with varying concentrations of human serum 
albumin (HSA) and immunoglobulin G (IgG) were analysed, before analysing patient clinical samples. 
Using a validated partial least squares method, the spiked samples (IgG) produced a linearity as high 
as 0.998 and a RMSEV of 0.49 ± 0.05 mg mL-1, with the patient samples producing R2 values of 0.992 
and a corresponding RMSEV of 0.66 ± 0.05 mg mL-1. This claim was validated using two blind testing 
models, leave one patient out cross validation and k-fold cross validation, achieving optimum linearity 
and RMSEV values of 0.934 and 1.99 ± 0.79 mg mL-1, respectively.  
This demonstrates that ATR-FTIR is able to quantify protein within clinically relevant complex matrices 
and concentrations, such as serum samples, rapidly and with simple sample preparation. The ability 
to provide a quantification step, along with rapid disease classification, from a spectroscopic signature 
will aid clinical translation of vibrational spectroscopy to assist with problems currently faced with 
patient diagnostic pathways.  
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1. Introduction 
The analysis of biofluids such as serum using vibrational spectroscopy is considered a potential 
solution to current problems with early and accurate diagnosis of many diseases [1] and promises 
improved patient mortality, morbidity and quality of life [2]. Biofluids are routinely obtained following 
a minimally invasive procedure, providing a large sample volume that contains biomolecular 
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components  such as proteins, amino-acids, lipids and carbohydrates in relative concentrations which 
are highly dependent on demographical characteristics and physiological or pathological status [3]. 
Clinicians establish a diagnosis from several criteria, including; medical history, clinical symptoms, 
imaging data and biological exploration. Numerous diseases are characterised by a qualitative or 
quantitative modification of a specific biological parameter, while others are associated with a 
biological signature, changes in multiple biological parameters [4],[5].  
Proteomics, peptidomics and metabolomics are often studied through nuclear magnetic resonance 
[6], mass spectrometry [7] or capillary electrophoresis [8]. A large number of proof-of-principle studies 
have identified diagnostic markers for cancers [9],[10],[11],[12]. However, there is extensive sample 
preparation associated with these techniques. ATR-FTIR can provide a spectral profile of all the 
macromolecular classes contained within serum and a signature, as opposed to single markers, could 
be advantageous when analysing a heterogenous disease such as cancer. Vibrational spectroscopic 
investigations have resulted in a large number of proof of principle studies that show promising 
results [13].  
The diagnosis of gliomas (high-grade and low-grade) from non-cancer through a combination of ATR-
FTIR and multivariate support vector machine analysis (SVM), was achieved with average sensitivities 
and specificities of 93.75 and 96.53 % respectively for human serum samples [14]. In 2016, a large 
serum study using FTIR spectroscopy was completed, reporting the discrimination of cancer vs non-
cancer patients with a sensitivity of 91.5 % and specificity of 83.0 %, as well as deciphering cancer 
severity and the primary site of metastasis [15]. These classification values were then improved to 
92.8 and 91.5 %, sensitivity and specificity, by executing Random forest and 2D correlation analysis in 
combination [16]. The application of vibrational spectroscopy to analyse tissue sections, as well as 
single cells [17], [18] has also been hugely successful. The advantages of vibrational spectroscopy, such 
as ATR-FITR, and high classification values demonstrates a potential use  as the gold standard for 
patient disease screening using serum [19], [20], [21].  
To facilitate the translation of an infrared spectroscopy based diagnostic test, the incorporation of a 
quantification step could be regarded as beneficial and complementary to current clinical practice as 
the majority of clinical tests are currently based upon quantitative values as opposed to signatures or 
fingerprints. Protein vibrations are often the most prominent in a biological infrared spectrum [22]. 
Furthermore, protein concentrations are systematically measured in routine practice; they are useful 
to interpret biological parameters, discuss nutritional status, extracellular hydration status or to help 
in the diagnosis of some diseases. Specific proteins such as human serum albumin (HSA) and 
immunoglobulinG (IgG), (as well as the ratio of the two), may be altered in the case of inflammation, 
infection, unexplained weight loss, fatigue or act as symptoms of kidney or liver disease [23],[24]. HSA 
constitutes between 57 – 71 % of the serum composition, and globulins 8 – 26 % [25]. HSA and IgG 
could be regarded as ideal to produce models in order to demonstrate an ATR-FTIR spectroscopic test 
capable of quantifying proteins.  
Infrared spectroscopy enables the production of a unique spectrum representative of the 
fundamental molecular vibrations that occur within the sample, that provides a ‘fingerprint’ of the 
sample [26], [27]. The combination of the rapid collection method obtained through the FTIR systems 
and spectroscopic method development has accelerated biomedical research using infrared 
spectroscopy. In particular, ATR-FTIR spectroscopy has been shown to be suitable for biological 
materials, due to the minimal sample preparation and the ability to analyse a variety of samples types, 
including serum [1], [28], [29], [30] . An advantageous property of IR based techniques, is that they 
obey the principles of the Beer Lambert law [31], allowing quantification of a given molecule relative 
to the absorbance of light in the sample it is travelling through. This enables ATR-FTIR spectroscopy to 
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quantify specific biomolecule concentrations, as the proportion of light absorbed by the sample will 
correlate with the concentration of molecules within a sample. 
This is evident from the wide variety of research carried out, quantifying particular biomarkers from 
biofluid samples [32], [33], [34]. For example, the analysis of dried serum deposits using transmission 
spectroscopy highlighted the ability to quantify eight serum analytes [35] and the simultaneous 
quantification of glucose and urea analytes in addition to malaria parasitaemia from a single drop of 
blood dried on a glass slide [36]. The latter highlights the capability of using ATR-FTIR spectroscopy to 
determine disease and metabolic state, through the identification and quantification of chemical 
parameters associated with the disease diagnosis. Furthermore, the concentration of in situ DNA 
within cells [37], as well as the metabolite concentrations in urine [38] and saliva [39], could be 
determined using ATR-FTIR and bovine IgG was quantified using transmission and ATR-FTIR 
spectroscopy [40]. The quantification of glycine, a low molecular weight fraction (LMWF), provided 
evidence that ATR-FTIR spectroscopy can monitor systemic spectral modifications created by spiking 
human serum with lyophilised glycine [41]. Additionally, the removal of high molecular weight 
fractions (HMWF), through centrifugal filtration, led to an increased precision and accuracy of the 
quantitative models based on the partial least squares algorithm [42]. Research carried out by Perez-
Guaita in 2012 [43], showed the possibility of determining total albumin, total globulin and 
immunoglobulin concentrations through the analysis of 50 µl liquid serum samples deposited on an 
ATR crystal cell. This work highlighted the potential for ATR-FTIR to act as a green alternative to current 
methods used within hospitals, through the removal of reagents and implementation of relatively 
cheap and simple instrumentation. However, no sample preparation study was performed in order to 
establish the optimum sample preparation with minute volumes of serum. 
Infrared spectral datasets are information rich, highlighting underlying biological and structural 
differences. Coupled with powerful multivariate analysis approaches, they have the ability to 
differentiate between disease classes by extracting relevant information. Multiple data mining 
approaches have been used in spectral data analysis, such as Principal Component Analysis (PCA), 
Random Forest (RF) and Support Vector Machine (SVM), all demonstrating the ability to discriminate 
diseased from non-diseased biofluid samples [44]. Currently, Partial Least Squares Regression analysis 
(PLSR) is one of the most frequently used techniques for the production of quantitative models, due 
to its ability to identify systematic variations of contributing factors and generate quantitative 
predictive models. This allows the prediction of unknowns, using the latent variables extracted from 
the regression model  [40], [32], [45], [46]. 
ATR-FTIR spectroscopy has the ability to detect minor differences in biofluid samples, with minimal 
sample preparation, and multiple proof-of-principle studies have highlighted the potential clinical use 
for such a technique. However, translation of ATR-FTIR spectroscopy has not occurred due to multiple 
factors, including the lack of acceptance from clinical environments. 
We show, for the first time, an optimised methodology to enable protein quantification in single and 
complex mixtures using a PLSR approach, detailing the in-depth progression of determining protein 
concentration from spiked samples, to patient samples, before blind testing methods. The 
incorporation of this new quantification step within biofluid diagnostic methodologies would enable 
a direct comparison to gold standard diagnostic methods and highlight the clinical excellence of 
vibrational spectroscopic analysis of biofluids and facilitate translation. 
2. Materials and Methods 
2.1. Sample Preparation Methodology 
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For the first time, an in depth methodological investigation was performed in order to establish the 
optimum sample preparation protocol for quantification from serum based ATR-FTIR spectroscopy. 
This study was performed using 2 models samples sets 1) Whole Serum Dilution Study and 2) Spiked 
Human Serum Models, before moving onto patient samples. Table 1 and subsections, 2.1.1 - 2.1.3, 
below provide further information on experimental details. 
 
2.1.1. Whole Serum Dilution Study 
To determine the ability of ATR-FTIR spectroscopy to detect variable protein concentrations, 1000 µl 
of commercially available, whole, sterile, filtered, mixed pool human serum (TCS Biosciences, UK) were 
used to create a set of seven 2- fold dilutions using deionised water (Milli-Q water (Millipore Elix S) 
 
2.1.2. Spiked Human Serum Models 
HSA and IgG (Sigma-Aldrich, UK) were used to create two spiked pooled serum models. Due to their 
abundant nature within human blood, current clinical use and detection over a range of 
concentrations from patient samples, these two proteins were deemed ideal for comparative 
measurements. Preparation of the two separate spiked models were created by the addition of each 
protein independently, while maintaining the concentration of the other.  The initial concentrations 
of HSA and IgG of 46.3 and 13.53 mg/ml, respectively, were also taken into consideration. Further 
details of this can be found in Table 1 and Supporting Information (SI Materials and Methods, Spiked 
Human Serum Models and Table S-1).  
 
2.2. Patient Sample Protein Levels 
Serum samples collected at the Biochemical laboratory at the University Hospital CHU Bretonneau de 
Tours, for the measurement of total protein, HSA and IgG were used for research, obeying the ethical 
procedures implemented by the hospital. The concentrations of total protein, HSA and IgG were 
measured using a Cobas 6000 analyser series (Roche Diagnostics) with a measurement precision of 
1g/L – (Table S-2). The samples were obtained following an in-house standard operating procedure, 
developed by the hospital for the routine analysis of serum samples. Whole blood was collected using 
a dry tube with separate gel and coagulation activator. After at least one hour of clotting, blood was 
centrifuged for 10 minutes at 3000 g to isolate the serum from the other blood components. Sera 
were then analysed by immunoturbidimetry (IgG and HSA) and a colorimetric assay based on copper 
reaction for total proteins. The remainder of the blood serum was stored at -20°C until ATR-FTIR 
experiments were carried out.  
 
2.3. Data Collection Using ATR – FTIR Spectrometer 
ATR-FTIR spectra were recorded using a diamond crystal and a single reflection golden gate accessory 
(Specac, UK) attached to a Bruker Vector 22 (Bruker, Germany). 32 co-added scans, covering a 
wavenumber range of 4000 – 400 cm-1, were combined to produce the spectrum, using a spectral 
resolution of 4 cm-1. A background spectrum (32 co-added scans), using the same spectral range, of 
the ambient conditions was automatically subtracted by the OPUS package version 4.2 (Bruker, 
Germany) to create the sample spectrum.  
 
The sample preparation approaches used are liquid, air dried and liquid samples which have been 
diluted by 10 %using deionised water, and then air dried (10 % air dried). Spectra from liquid serum 
samples were obtained in triplicate, immediately after the drop was deposited on to the crystal. Dry 
serum samples (air dried and 10% air dried) were also obtained in triplicate, following a drying time 
of between 5 – 8 minutes.  The triplicate analysis of each serum drop accounted for any instrumental 
variance This process was repeated five times to encompass any biological variance between the 
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samples. The serum was dropped at a perpendicular angle using a micropipette to ensure a high level 
of reproducibility. This led to the production of a spiked data set containing 105 spectra and a patient 
data set containing 300 spectra, for analysis. Information on how the samples were confirmed as dry 
and the triplicate analysis is included in Supporting Information (Materials and Methods, Data 
Collection Using ATR – FTIR Spectrometer). 
 
2.4. Data Pre-Processing and Analysis 
Matlab (Mathworks, USA) was used to carry out all pre-processing and data analysis. A rubber-band 
baseline correction and vector normalisation using University of Strathclyde, in house written 
software was applied to the fingerprint region (1800 - 900 cm-1) (Figure 1). Pre-processing allowed the 
systematic increase of the two protein concentrations to be observed and assessed, by removing any 
non-biochemical components of the spectra and enabling clearer analysis of spectral variations in the 
amide region.   
 
PLSR was used to quantify the prepared protein concentrations from the spiked samples as well as 
estimate the serum protein levels in patient samples. The algorithm is a supervised method, whereby 
the concentrations are provided to the model prior to running the analysis. The PLSR models discussed 
have been built from the pre-processed data sets. The analysis gives an estimated value for the model 
accuracy [47] and is termed the Root Mean Square Error (RMSE), as well as an R2 value indicating the 
linearity between the experimental and the predicted concentrations.  
 
2.5. Whole Serum Dilution Study PLSR Optimisation 
During the PLSR optimisation step, mean spectra were identified following pre-processing to calculate 
the area under the curve (AUC) and determine whether ATR-FTIR can detect and quantify protein 
concentrations. This was carried out on pure air dried and pure liquid, 2-fold dilution, samples to 
determine if a dilution factor was required.  
 
2.6. Spiked and Patient Model Validation 
To validate the robustness of the PLSR predictive models, the optimum number of cross validation 
loops was determined, by re-sampling 512 cross validation iterations, 1000 times. This produced three 
convergence plots, for the outputs of the RMSE calibration (RMSEC), RMSE validation (RMSEV) and R2 
values (Figure 2). From this plot, the optimum number of cross validation loops could be determined 
to produce minimal variation in the output from the PLSR analysis. This was done by curve fitting a 
one term power series model to the data and calculating when the gradient was <0.0001. The highest 
number of iterations was selected from the three convergence plots, with the result that the number 
of cross validation loops was not the same for each protein, but was consistently selected as the 
largest. For each iteration, the calibration set was compiled from 50 % of the data, selected randomly, 
leaving the remaining 50 % to be used for the validation set for the quantitative predictions. The mean 
and standard deviation of the RMSE and R2 were calculated from each iteration. This methodology 
was carried out prior to all PLSR analysis in order to validate any results obtained, as PLSR is a 
supervised method and may be prone to overfitting the data. Once the ability of ATR-FTIR 
spectroscopy to determine the protein concentration of spiked as well as patient samples was 
identified, the patient set was used to blindly test the models.  
 
2.7. Blind Testing Model Validation 
The patient sample dataset was then used to create both the calibration and validation sets. To begin 
with, a leave one patient out cross validation (LOPOCV) method was employed, whereby 19 patient 
samples were used as the training set and the remaining 1 was used to test the model. A similar 
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methodology was then repeated, whereby 15 patients were selected to act as the training set, leaving 
the remaining 5 to act as the test set and be blindly predicted, in a process termed K-fold cross 
validation. Both approaches were optimised ensuring the maximum number of combinations were 
carried out as cross validation iterations. As such, this led to the former approach being repeated to 
cover all 20 possible combinations of selecting one patient out of 20, and the latter approach carried 
out over all the 15,504 possible combinations of selecting five from 20 patients. As the IgG 
concentration from patient 18 was not available (Table S-2), the model validation for the IgG 
concentrations was based on 19 patients as opposed to 20. Thus, the training sets contained 18 and 
14 patients, for the LOPOCV and the K-fold methodologies respectively, reducing the number of 
possible combinations to 19 and 11,628, respectively. 
 
3. Results and discussion 
3.1. Quantification of protein concentrations in spiked human serum 
3.1.1. Determining dilution factor 
The analysis of biofluids, such as serum, using ATR-FTIR, produces high quality spectra with clearly 
defined spectral features [48]. In an ATR-FTIR spectrum, spectral peaks can be assigned to particular 
biomolecules, in order to allow the function, structure and biochemical signature of the sample to be 
identified [28]. Due to the strong water absorbance of IR light, air dried samples are generally 
preferred over liquid samples, although the biomolecular composition of the serum is unchanged [49]. 
The spectra of air dried pooled human serum exhibit the expected spectral features and assignments 
associated with human serum (Figure 3). These can be briefly described as; 3280 cm-1 (H-O-H 
stretching), 2957 cm-1 (asymmetric CH3 stretching), 2920 cm-1 (asymmetric CH2 stretching), 2872 cm-1 
(symmetric CH3 stretching), 1650 cm-1 (amide I of proteins), 1536 cm-1 (amide II of proteins), 1453 cm-
1 (CH2 scissoring), 1394 cm-1 (C=O stretch of COO-), 1242 cm-1- (asymmetric PO2 stretch), 1171 cm-1 
(ester C-O symmetric stretch) and 1080 cm-1 (C-O stretch) [50]. The spectra are strongly dominated by 
the abundant proteins contained in the serum, which are present in high concentration compared to 
the other low molecular weight (LMW) components. In fact, the amide I peak at 1650 cm-1 has the 
highest intensity within the entire spectrum.  
 
Figure 3 also shows the spectra of serum solutions which have been serially diluted before drying. The 
spectral peak centroids identified and assigned above remain unchanged by the dilution process, and 
the impact of the dilution procedure can be monitored by plotting the integrated area under the curve 
of the fingerprint region, as shown in Figure 3 (right). The curve shows an approximate linear 
dependence of integrated absorbance as a function of concentration in the low concentration region, 
but the behaviour rapidly deviates from linearity above 30% dilution. Notably, after 50 % dilution of 
the stock solution, the integrated absorbance decreases by only less than 5 %. The nonlinearity and 
saturation of the absorbance of dried deposits measured by ATR-FTIR, as a function of solution 
concentration has previously been discussed by Bonnier et al. [41]. Importantly, for the methodology 
employed in the current study, in order to produce the models spiked with protein, further protein 
will need to be added to the pooled serum to incorporate a wide concentration range. The minimal 
change in absorption above a 50 % dilution factor, shown in Figure 3 suggests the identification of an 
upper detection limit for the volume deposited. Therefore, for the analysis of the air dried serum, a 
dilution factor of 10 %, is required to ensure different protein concentrations are observable. This 
could also could have been combatted experimentally by depositing smaller volumes. However, to 
satisfy the requirement to cover the entire internal reflection element (IRE) and reproducible 
pipetting, diluting the larger volume was determined to be the optimum experimental approach.  
 
In contrast, following the analysis of the liquid samples, biomolecular spectral assignments are 
difficult, due to the dominant water contribution from the broad O-H stretching band around 
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3300 cm-1 and bending vibration around 1680 cm-1, (Figure 4). The AUC plot, shown in Figure 4 (right), 
indicates that serum dilution has a minimal effect on the integrated absorbance over the 
concentration range, although a linear decrease is observed below the 6.25 % dilution, with an R2 
value of 0.9979, which may be associated with a disaggregation phenomenon [51], therefore no 
dilution is necessary. 
 
 
3.1.2. Construction of the quantitative model: partial least square regression (PLSR 
Prior to the analysis of patient samples, a quantitative model using the PLSR algorithm was produced 
to evaluate the ability of ATR-FTIR to quantify protein concentration within a complex medium, such 
as human serum. This was applied to the protein spiked human serum models that reflect the clinically 
relevant protein concentrations, which tend to lie outside the normal ranges of 34 – 54 mg/ml for HSA 
and 8.1 – 23 mg/ml for IgG, within human blood in order to optimise the protocol. 
 
Figure 5 shows the mean (n = 9) ATR-FTIR spectral fingerprint region for spectra obtained from IgG 
spiked, 10% diluted air dried serum samples. The data shows an increasing absorbance trend moving 
from the stock solution (red) to the highest concentration of protein (black), highlighting the 
systematic increase in the protein amide bands at 1640 and 1560 cm-1 associated with the increased 
concentration of IgG. 
 
To determine any relationship between variations in the spectra and the protein concentrations (HSA 
and IgG), PLSR analysis was conducted. The optimum number of dimensions was selected by plotting 
the RMSE from the validation set vs. the number of dimensions, and an example of such a plot, for the 
10% diluted air dried albumin analysis, is shown in Figure 6. For consistency, the minimum point on 
the curve was selected, in this case the 8th dimension, determined at 2.347 ± 0.2788 mg mL-1. This 
information is fed into a predictive model to compare the estimated concentrations from the spectral 
data set to the known concentrations from the produced solutions.  
 
Table 2 summaries the predictive values from the protein spiked models, also provided in Supporting 
Information (SI Results and Discussion, Figure S-2). By comparing the R2 values, as well as the RMSE of 
the validation set (RMSEV), the best overall result came from the 10 % diluted air dried samples. These 
results show that concentrations can be estimated unambiguously and that dilution ensures that the 
protein absorbances are within the range of validity of the Beer-Lambert Law. Results highlight that, 
after air drying, consistent and reproducible spectra are obtained. The best individual result came 
from the pure air dried IgG spiked samples, the linearity being, R2 = 0.998 and the RMSEV 
being 0.49 ± 0.05 mg mL-1.  
 
Summarising, the standard deviations across all the predictive values represent good repeatability 
between the cross-validation iterations. As the 10 % diluted air dried samples produce the best overall 
predictive values, this sample preparation protocol was adopted for the analysis of the patient 
samples. Interestingly, the PLSR models from the liquid samples produce comparable predictive 
results to the air dried samples. Due to the speed and ease of acquiring liquid ATR-FTIR spectra, given 
the removal of the rate determining step (5-8 minute drying time), the liquid sample state was also 
considered in the patient sample analysis steps. 
 
It was necessary to carry out these methodological analysis steps before progressing to patient 
samples and model blind testing, to establish the optimum sample preparation protocol, leading to 
the best possible predictive values. While the work carried out by Perez et al. showed excellent results, 
this particular type of methodology development procedure was not considered. This led to protein 
quantification of 50 µl liquid serum samples using an ATR crystal cell, potentially missing the 
demonstrated potential of diluted serum sample analysis [43].  
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3.2. Protein level quantification in patient samples 
Due to the natural biological variation between individuals, the analysis of patient samples can be 
considered more challenging than spiking commercially available pooled human serum. Spiking a 
sample with a known amount of a specific biological component can model one physiological change, 
whilst everything else remains consistent. Between patients, the composition of blood can vary for 
multiple reasons, including diet, time of sample collection, as well as their disease state. During routine 
blood analysis, multiple biomolecular concentrations are measured, including the total protein 
concentration made up mainly of HSA and immunoglobulins. It is therefore important to analyse 
patient samples in order to understand the potential variance in the spectral response in order for 
these spectra to be used for clinical purposes. As the 10 % diluted air dried samples produced the best 
predictive models, the patient samples were analysed in this sample state. In addition, the patient 
samples were also analysed in the liquid form, due to the promising performance of these samples 
during calibration and the shorter collection time which is an important parameter in clinical 
situations.  
 
3.2.1. 10 % Diluted Air Dried Patient Samples 
A new PLSR model was calculated based on the 20 patient samples using the 10 % diluted air dried 
sample preparation, as listed in Table 3 and further detailed in Supporting Information (SI Results and 
Discussion, Figure S-3). For the quantification of total protein concentration, a RMSEV of 0.662 ± 0.046 
mg mL-1 and an R2 value of 0.992 was achieved. This result suggests that, despite moving to a more 
complex serum sample, a high level of predictive power is maintained and the relationship between 
the spectral variations and the total protein concentration is linear, within standard deviation. 
Quantification of the individual protein concentrations resulted in the HSA performing better than the 
spiked model and the IgG performing poorer than the spiked model, when examining the RMSEV and 
R2 values detailed in Table 2 (spiked) and 3 (patient). 
 
3.2.2. Liquid Patient Samples 
Similarly, the results from the PLSR analysis of the 20 patient liquid samples are detailed in Table 3 
and provided in Supporting Information (SI Results and Discussion, Figure S-3). It is evident that the 
RMSEV values are relatively consistent with those achieved for the spiked samples. The HSA patient 
model produced a result of 2.56 ± 0.35 mg mL-1, compared to the HSA spiked models result of 
3.065 ± 0.290 mg mL-1. However, when comparing the RMSEV values of the patient liquid to the 
patient 10% diluted air dried samples, the results are dramatically higher. This suggests that the 
analysis of the liquid patient samples produce models with a reduced predictive power. 
 
When considering the R2 values, results show that the values for the liquid patient samples are 
considerably lower than both the spiked models and the 10 % diluted air dried patient samples. The 
drop-in linearity implies the spectral variations and the protein concentrations show less correlation; 
the best result achieved was 0.831 for the total protein concentration, dramatically less than the 0.962 
achieved for the analysis of the sample patient set in the 10 % diluted air dried state. The error bars 
displayed on the plot (Figure 7) are increased in size and in some areas, show overlap. From this 
analysis, it is evident that the patient sample concentrations cannot be quantified unambiguously.  
 
3.3. Model Validation 
Following the determination of the optimal sample states from predicting the spiked samples and then 
clarifying using the patient sample concentrations, the next stage was to determine the ability of ATR-
FTIR spectroscopy to predict unknown protein concentrations from serum. This was done by blind 
testing, removing information of the concentrations from the model.  
 
3.3.1. Leave One Patient Out Cross Validation (LOPOCV) of Patient Based Model 
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The first method of validating the use of ATR-FTIR spectroscopy to predict serum protein 
concentrations involved the use of a LOPOCV process. From the results in Table 4, it is evident that 
the prediction of the total protein concentration produced the best results, with an RMSEV of 
1.534 ± 1.14 mg mL-1 and an R2 value of 0.926. The prediction of individual HSA and IgG concentrations 
were not as effective as the total protein concentration, represented by higher RMSECV values for 
both proteins. The high standard deviation of the IgG data (± 2.14), results in the model not being able 
to identify individual patient concentrations with precision. The R2 values for both proteins are also 
lower than those of the total protein concentration, showing correlation between spectral variations 
and concentrations decreases. 
 
3.3.2. K-fold Cross Validation of Patient Based Model 
A similar trend to the LOPOCV is apparent in Table 4. The total protein content allows for the best 
predictive values, followed by the HSA and then the IgG. The RMSECV for the total protein 
concentration prediction is higher (1.99 ± 0.78 mg mL-1) than the LOPOCV model, but the lower 
standard deviation suggests that this is a more precise method. For this reason, the R2 value of 0.934 
is also higher than that of the previous method, showing more linearity between the predicted and 
observed concentrations. The prediction of the individual proteins shows the same trend. For both 
HSA and IgG, the k-fold blind testing produces less accurate results, in comparison to the true result 
but with more precision and reduced statistical variability. The linearity of the models decreases and 
again highlights that a linear relationship between the spectral variations and the concentrations. 
 
Both the LOPOCV and k-fold blind testing methods produced promising results with similar trends, 
specifically for the prediction of total protein concentration. The reason for the poor IgG results could 
be due to the inability to differentiate between the variable contributions of the five major types of 
immunoglobulin present within human blood  (IgA, IgG, IgM, IgE and IgD) [52].    
 
4. Conclusions 
Vibrational spectroscopy is widely used for the analysis of biofluids and many proof-of-principle 
studies have shown the capability of techniques like ATR-FTIR spectroscopy to enable disease 
detection, as well as quantification of biomolecules However, the translation of vibrational 
spectroscopy into a clinical environment is dramatically impacted by the inability to perform a direct 
comparison to the current quantitative diagnostic measurements. Current clinical practice uses blood 
protein concentration as a non-specific disease indicator, possibly leading to further investigation and 
potentially a diagnosis, highlighting the advantageous nature of protein quantification.  
 
The work presented showcases for the first time the development of the optimal methodology for the 
quantification of protein biomarkers in a complex background (namely 10% diluted air dried serum 
analysis), the inclusion of this methodology into vibrational spectroscopic diagnostics of biofluids 
could bridge the gap between vibrational spectroscopy and clinical practice. In addition, the drying 
process could be accelerated through the implementation of heating mantle, the use of a smaller 
sample volume or batch drying, before analysis. 
This study shows how ATR-FTIR spectroscopy can be used to quantify proteins in spiked and patient 
samples, rapidly, economically and with simple sample preparation. Linearity values as high as 0.992, 
in addition to high accuracy and precision demonstrated by RMSEV values such as 0.662 ± 0.046 mg 
mL-1, indicate that quantification of clinically relevant molecules can be conducted using this approach. 
The blind testing of patient clinical samples, while maintaining desirable linearity (R2 = 0.934), precision 
and accuracy (RSMEV = 1.986 ± 0.778 mg mL-1), illustrates the potential use of this technique within a 
clinical setting and its incorporation could bridge the gap between vibrational spectroscopy and 
current clinical analyses. The development of a quantification step in addition to disease 
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differentiation shows great promise to enable a dynamic clinical diagnostic platform that can improve 
the current patient diagnostic pathway.  
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Figure 1 – Highlighting spectral pre-processing steps. From left to right, raw data, baseline corrected data and finally 
baseline corrected and vector normalised. 
Figure 4 - Left: Mean ATR-FTIR spectra collected from the analysis of the liquid 2-fold dilution set of pooled serum 
Red: 0 % serum, Pink: 3.125 %, Yellow: 6.25 %, Orange: 12.5 %, Green: 25 %, Blue: 50 % and Black: 100 % 
Stars highlight peaks of interest. Right: AUC plot from the fingerprint region. 
Figure 3 – Left: Mean ATR-FTIR spectra collected from the analysis of the air dried 2-fold dilution set of pooled serum. 
Red: 0 % serum, Pink: 3.125 %, Yellow: 6.25 %, Orange: 12.5 %, Green: 25 %, Blue: 50 % and Black: 100 % 
Stars highlight peaks of interest. Right: AUC plot from the fingerprint region. 
Figure 2 –A representative convergence plot of the R2 value +/- SE vs. the no. of iterations from the 10 % diluted air 
dried globulin analysis. This particular plot led to the selection of 26 iterations which was compared to the number 
selected from the RMSEC and the RMSEV plots, before the highest value was selected and taken forward to the PLSR 
analysis 
Figure 7 - Predictive model built from the PLS analysis of the liquid IgG patient samples. For each concentration the 
values displayed are an average of the concentration predicted from the iterations of the cross validation. Shown on 
the plot is the RMSEV, R2 and the standard deviation corresponding to each of the values. 
Figure 5 – Mean ATR-FTIR fingerprint spectra following the analysis of the 10 % diluted air dried, IgG spiked samples. 
Red: 13.53 mg/ml, Pink: 18.48 mg/ml, Yellow: 23.58 mg/ml, Orange: 28.53 mg/ml, Green: 33.48 mg/ml, Blue: 38.58 
mg/ml and Black: 43.53 mg/ml.   
Figure 6 - Evolution of the root mean square error on the validation set (RMSEV). In this case, values are averaged from 
the 234 cross validations.  
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X: 8  
Y: 2.347 
Y Delta: [-0.2788 0.2788] 
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Table 1 - Experimental details 
 
Table 2 – Summary of the RMSEV ± STD and R2 values from the predictive models, for the two protein spikes 
 
Table 3 - Summary of the RMSEV ± STD and R2 values from the three predictive models, for the two patient sample states 
 
Table 4 - Summary of the RMSEV ± STD and R2 values from the two blind predictive models, for the three different protein 
concentrations of the 10 % diluted air dried samples 
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  Spiked Human Serum Models  
 Whole Serum Dilution Study HSA IgG 
Sample 
Preparation 
2 - fold dilutions from pure 
human pooled serum 
0.14 g HSA/2000 µl human 
pooled serum 
0.06 g IgG/2000 µl human 
pooled serum 
Sample 
Concentrations 
100, 50, 25, 12.5, 6.25, 
3.125, 0 % 
116.3, 106.29, 96.28, 86.27, 
76.33, 66.32, 46.3 mg mL-1 
43.53, 38.58, 33.48, 28.53, 
23.58, 18.48, 13.53 mg mL-1 
Sample States 
Analysed 
10 µl liquid, 
1 µl pure air dried 
10 µl liquid, 
1 µl pure air dried, 
2 µl 10% diluted air dried 
10 µl liquid, 
1 µl pure air dried, 
2 µl 10% diluted air dried 
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Protein 
Air Dried  Liquid  10 % Diluted Air Dried  
RMSECV ± STD (mg mL-1) R2 RMSECV ± STD (mg mL-1) R2 RMSECV ± STD (mg mL-1) R2 
HSA 4.585 ± 0.568 0.959 3.065 ± 0.290 0.982 2.347 ± 0.287 0.989 
IgG 0.487 ± 0.053 0.998 2.365 ± 0.194 0.947 0.861 ± 0.104 0.993 
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Protein 
10 % Diluted Air Dried  Liquid  
RMSECV ± STD (mg mL-1) R2 RMSECV ± STD (mg mL-1) R2 
Total 0.662 ± 0.046 0.992 3.080 ± 0.483 0.831 
HSA 0.848 ± 0.064 0.976 2.556 ± 0.351 0.780 
IgG 1.945 ± 0.134 0.812 2.982 ± 0.346 0.566 
  26 
 
Protein 
LOPOCV  K-Fold CV  
RMSEV ± STD (mg mL-1) R2 RMSEV ± STD (mg mL-1) R2 
Total 1.534 ± 1.140 0.926 1.986 ± 0.778 0.934 
HSA 2.029 ± 1.260 0.890 2.491 ± 0.849 0.805 
IgG 3.582 ± 2.140 0.827 4.464 ± 1.460 0.454 
